Downloaded on October  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/44929

Related Commentary, page 844  

Research article

MEK-ERK pathway modulation ameliorates 

disease phenotypes in a mouse model  

of Noonan syndrome associated  

with the Raf1L613V mutation

Xue Wu,1,2 Jeremy Simpson,3,4 Jenny H. Hong,1,2 Kyoung-Han Kim,3  

Nirusha K. Thavarajah,2 Peter H. Backx,3 Benjamin G. Neel,1,2 and Toshiyuki Araki2

1Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. 2Campbell Family Cancer Research Institute,  

Ontario Cancer Institute and Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada.  

3Department of Physiology and Medicine, Heart and Stroke/Richard Lewar Centre, University of Toronto, Toronto, Ontario, Canada.  

4Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada.

Hypertrophic	cardiomyopathy	(HCM)	is	a	leading	cause	of	sudden	death	in	children	and	young	adults.	
Abnormalities	in	several	signaling	pathways	are	implicated	in	the	pathogenesis	of	HCM,	but	the	role	of	the	
RAS-RAF-MEK-ERK	MAPK	pathway	has	been	controversial.	Noonan	syndrome	(NS)	is	one	of	several	auto-
somal-dominant	conditions	known	as	RASopathies,	which	are	caused	by	mutations	in	different	components	
of	this	pathway.	Germline	mutations	in	RAF1	(which	encodes	the	serine-threonine	kinase	RAF1)	account	for	
approximately	3%–5%	of	cases	of	NS.	Unlike	other	NS	alleles,	RAF1	mutations	that	confer	increased	kinase	
activity	are	highly	associated	with	HCM.	To	explore	the	pathogenesis	of	such	mutations,	we	generated	knockin	
mice	expressing	the	NS-associated	Raf1L613V	mutation.	Like	NS	patients,	mice	heterozygous	for	this	mutation	
(referred	to	herein	as	L613V/+	mice)	had	short	stature,	craniofacial	dysmorphia,	and	hematologic	abnormali-
ties.	Valvuloseptal	development	was	normal,	but	L613V/+	mice	exhibited	eccentric	cardiac	hypertrophy	and	
aberrant	cardiac	fetal	gene	expression,	and	decompensated	following	pressure	overload.	Agonist-evoked	MEK-
ERK	activation	was	enhanced	in	multiple	cell	types,	and	postnatal	MEK	inhibition	normalized	the	growth,	
facial,	and	cardiac	defects	in	L613V/+	mice.	These	data	show	that	different	NS	genes	have	intrinsically	dis-
tinct	pathological	effects,	demonstrate	that	enhanced	MEK-ERK	activity	is	critical	for	causing	HCM	and	other	
RAF1-mutant	NS	phenotypes,	and	suggest	a	mutation-specific	approach	to	the	treatment	of	RASopathies.

Introduction
Cardiac hypertrophy is a major way by which cardiomyocytes 
respond  to  various  stresses,  including  abnormal  neurohor-
monal stimuli, hemodynamic overload, and injury. There are 
2 general types of cardiac hypertrophy (1, 2): physiological, 
which is associated with exercise or pregnancy, and pathologi-
cal, whose primary cause is genetic defects (termed primary 
hypertrophy); and excessive afterload, resulting from condi-
tions such as hypertension or valvular stenosis (termed sec-
ondary hypertrophy). With increased cardiac stress, cardiac 
hypertrophy may initially represent a compensatory response 
of the myocardium. However, chronic pathological hypertrophy 
predisposes to ventricular dilatation, heart failure, arrhythmia, 
and/or sudden death (3, 4). Physiological hypertrophy is typi-
cally concentric, with preservation of chamber shape, absence of 
inflammation or fibrosis, and normal cardiac gene expression. 
In contrast, pathological hypertrophy eventually progresses to 
chamber dilatation (eccentric hypertrophy), is often associated 
with fibrosis, and typically leads to the reactivation of a fetal 
gene expression program characterized by increased levels of 
(among others) atrial natriuretic peptide (ANP), brain natri-
uretic peptide (BNP), and β–myosin heavy chain (β-MHC) (5).  

Authorship	note: Xue Wu and Jeremy Simpson contributed equally to this work.
Conflict	of	interest: The authors have declared that no conflict of interest exists.
Citation	for	this	article: J Clin Invest. 2011;121(3):1009–1025. doi:10.1172/JCI44929.

Delineating the molecular pathways that distinguish physi-
ological and pathological hypertrophy, and identifying ways to 
reverse the latter, are of obvious medical importance.

Primary hypertrophic cardiomyopathy (HCM), the prototypic 
genetic form of pathological hypertrophy, is a leading cause of 
sudden death in the young (6). The hallmark of HCM is cardiac 
hypertrophy in the absence of an obvious inciting hypertrophic 
stimulus (7). Mutations in genes encoding sarcomeric proteins 
(e.g., β-MHC, cardiac troponin T, and myosin-binding protein 
C) account for approximately 75% of primary HCM cases. Such 
mutations usually alter sarcomere structure and function and 
result in mechanical, biochemical, and/or bioenergetic stresses 
that activate cardiomyocyte signaling pathways to mediate the 
hypertrophic phenotype (8–11). Aberrant activation of hypertro-
phic signaling pathways can themselves result in hypertrophy. 
For example, germline mutations in AMPK are a rare cause of 
HCM (12–14). Moreover, genetic and cellular models have iden-
tified multiple signaling systems that can cause or contribute 
to pathological hypertrophy, including the calcineurin-NFAT, 
PI3K-Akt-mTOR, glycogen synthase kinase–3β (GSK-3β), and 
JNK pathways (1, 2, 15). The detailed mechanism by which aber-
rant activation of these pathways evokes pathological hypertro-
phy remains incompletely understood.

The RAS-RAF-MEK-ERK MAPK pathway (referred to herein 
as the RAS-ERK pathway) is a central signaling cascade evoked 
by multiple agonists, including growth factors (e.g., Heregulin, 

	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 3      March 2011 

1009

Downloaded on October  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/44929

research article

Figure 1
Generation of inducible Raf1L613V knockin 
mice.  (A)  Targeting  strategy.  Structures 
of the Raf1 locus, targeting vector, mutant 
allele, and location of probes for Southern 
blotting are shown. (B) Correct targeting of 
ES cells. Genomic DNA from WT ES cells 
and PCR-positive L613Vfl/+ ES clones was 
digested with XbaI (5′ and Neo probe) or 
BamHI (3′ probe) and subjected to Southern 
blotting with 5′, 3′, or Neo probes. Blots with 
5′ and 3′ probes were run on the same gel 
but were noncontiguous (white lines). (C) 
Expression of Raf1L613V allele is inducible. 
RNA was isolated from WT and L613Vfl/+ 
ES cells with or without prior transfection of 
MSCV-Cre-GFP plasmid and reverse tran-
scribed into cDNA. A PCR product, obtained 
by  using  primers  within  exon  11  and  at 
the end of exon 16 of the Raf1 cDNA, was 
digested with DraIII. Note that the mutant 
allele was silent until Cre was introduced, 
and then was expressed efficiently.

IGF-I, EGF, and PDGF), cytokines (e.g., IL-6, cardiotrophin, and 
leukemia inhibitory factor [LIF]), G protein–coupled receptor 
(GPCR) agonists (e.g., angiotensin II [Ang II] and β-adrenergic 
agonists), and physical stimuli (e.g., mechanical stretch), in car-
diomyocytes as well as other cell types (1, 2, 16). The pathway 
is initiated by activation of RAS, which requires RAS–guanine 
nucleotide exchange factors (RAS-GEFs) such as SOS1 and, in 
most cell types, the protein-tyrosine phosphatase SHP2 (encoded 
by PTPN11). RAS recruits RAF proteins (e.g., RAF1, BRAF, and 
ARAF) to the cell membrane, where they are activated and sub-
sequently form complexes with MEK1/2 and ERK1/2, aided by 
scaffolds such as KSR. Activated RAF proteins phosphorylate 
MEK1/2, which in turn phosphorylates ERK1/2. ERKs phosphor-
ylate cytosolic substrates and also translocate to the nucleus to 
stimulate diverse gene expression programs by phosphorylating 
several transcription factors (16, 17).

The role of the RAS-ERK pathway in cardiac hypertrophy has 
been controversial. Some data argue that excessive activity of this 
pathway causes HCM, whereas other evidence suggests involve-
ment in physiological, but not pathological, hypertrophy (18, 19). 
Transgenic mice with cardiac-specific expression of oncogenic 
HRas (G12V) display significant cardiac hypertrophy, decreased 
contractility,  diastolic  dysfunction  associated  with  intersti-
tial fibrosis, induction of cardiac fetal genes, and sudden death 
(20–22), all of which are consistent with HCM. In cultured car-
diomyocytes, depletion of Erk1/2 with antisense oligonucleotides 
or pharmacological inhibition of Mek1/2 attenuates the hypertro-
phic response to agonist stimulation (23, 24). Mice with cardiac-
specific overexpression of dominant-negative Raf1 have no overt 
phenotype, but they are resistant to the development of cardiac 

hypertrophy in response to pressure overload (25), which sug-
gests that signals from Raf1 are necessary for the hypertrophic 
response. On the other hand, transgenic mice expressing an acti-
vated Mek1 allele under the control of the α-MHC promoter have 
concentric hypertrophy with enhanced contractile performance, 
show no signs of decompensation over time, and reportedly do 
not progress to pathological hypertrophy (26). A recent study even 
argued against any role for ERK1/2 in cardiac hypertrophy, as 
Erk1–/–Erk2+/– mice, as well as transgenic mice with cardiac-specific 
expression of dual specificity phosphatase 6 (Dusp6), an ERK1/2-
specific phosphatase, showed a normal hypertrophic response to 
pressure overload and exercise (27).

Over the past 10 years, germline mutations in genes encoding sev-
eral members of the RAS-ERK pathway have been identified in a set 
of related, yet distinct, human developmental syndromes (28–32), 
now collectively termed the RASopathies (31, 32). These disorders, 
some (but not all) of which include HCM as a syndromic phenotype, 
present an opportunity to clarify the role of the RAS-ERK pathway 
in cardiac hypertrophy. Noonan syndrome (NS), a relatively com-
mon autosomal-dominant disorder with an occurrence of 1 in about 
1,000–2,500 live births, typically presents with proportional short 
stature, facial dysmorphia, and cardiovascular abnormalities. About 
25%–50% of NS patients exhibit some form of myeloproliferative dis-
order (MPD), which is usually transient and resolves spontaneously; 
rarely, NS patients develop the severe childhood MPD juvenile myelo-
monocytic leukemia (JMML) or other forms of leukemia (33). Muta-
tions in PTPN11 that increase SHP2 phosphatase activity account for 
approximately 50% of NS cases (34); other known NS genes include 
SOS1 (~10%; refs. 35, 36), RAF1 (3%–5%; refs. 37, 38), KRAS (1%–2%; 
refs. 39, 40), NRAS (<1%; ref. 41), and SHOC2 (<1%; ref. 42).

1010	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 3      March 2011

Downloaded on October  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/44929

research article

Figure 2
L613V/+ mice show multiple NS phenotypes. (A) Short stature in L613V/+ mice. Gross appearance of 2-month-old WT and L613V/+ male mice 
and growth curves of WT (n = 45) and L613V/+ (n = 45) male mice are shown. Differences were significant at all time points (P < 0.0001, 2-way 
repeated-measures ANOVA; ***P < 0.0001, Bonferroni post-test). (B) L613V/+ mice have facial dysmorphia. Gross facial appearance and repre-
sentative μCT scans of skulls from WT and L613V/+ mice. Double-headed arrows indicate inner canthal distance. See Table 1 for morphometric 
measurements. (C) Cytokine-independent myeloid colonies from BM of 2-month-old mice (n = 6 per genotype). ***P < 0.0001, 2-tailed Student’s 
t test. (D) Splenomegaly in L613V/+ mice. Representative gross appearance and spleen weight/BW ratio in WT (n = 25) and L613V/+ (n = 25) 
mice at 4 months. ***P < 0.0001, 2-tailed Student’s t test. (E) Increased total wbcs, neutrophils (NE), and monocytes (MO) in 1-year-old L613V/+ 
mice (n = 8 per genotype). *P < 0.05, ***P < 0.0001, 2-tailed Student’s t test.

Although NS patients typically have valvuloseptal defects, approx-
imately 20% have HCM (43). Moreover, different NS genes are dif-
ferentially associated with HCM. Only approximately 10% of NS 
patients with PTPN11 mutations (44) and approximately 20% of 
those with mutations in SOS1 (35) develop HCM. By contrast, HCM 
is found in approximately 95% of patients bearing RAF1 mutations 
that cause increased kinase activity (37, 38). The frequency of HCM 
also varies in other RASopathies. HCM is the most frequent (~80%) 
cardiovascular manifestation of LEOPARD syndrome (LS), caused 
by phosphatase-inactivating mutations of PTPN11 (45–48), but also 
is common (~50% in each) in Costello syndrome (CS), caused by 
gain-of-function mutations in HRAS (49, 50), and cardio-facio-cuta-
neous (CFC) syndrome, caused by BRAF, MEK1, or MEK2 mutations 
(51–53). Whether these differences represent differential effects of 
specific RAS-ERK pathway mutations, the effects of modifiers in the 
outbred human population, or both remains unclear.

Mouse models have begun to address such issues and to provide 
insight into the detailed pathogenesis and potential therapeutic 
approaches to these disorders. For example, we previously gen-

erated a knockin mouse model of the NS-associated Ptpn11D61G 
mutation that recapitulates the major features of NS, including 
short stature, facial dysmorphia, mild MPD, and valvuloseptal 
defects. These mice, like most PTPN11 mutant NS patients, do 
not have HCM (54). Transgenic mice expressing a different NS-
associated Ptpn11 mutant, Q79R, also show valvuloseptal defects 
and facial abnormalities seen in NS patients, which are prevented 
by genetic ablation of Erk1/2 and prenatal pharmacological inhi-
bition of Mek, respectively (55–57). Genetic ablation of Erk1 also 
prevents the development of valvuloseptal defects in mice express-
ing a highly activated Ptpn11 mutant in endocardial cells (58). 
A knockin mouse model of CS caused by the HRasG12V mutation 
shows HCM, but these mice also have aortic stenosis, making it 
unclear whether hypertrophy is primary or secondary (59).

Here, we have generated knockin mice expressing the kinase-acti-
vating NS mutant Raf1L613V. Similar to Ptpn11 mutant mice, mice 
expressing this Raf1 allele had short stature, facial dysmorphia, and 
hematological abnormalities; however, they did not have valvulos-
eptal defects, but instead developed HCM. Remarkably, nearly all 

	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 3      March 2011 

1011

Downloaded on October  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/44929

research article

Table 1
Morphometry of skulls from 2-month-old WT and L613V/+ 
male mice

	
Length (mm) 
Width (mm) 
Width/length ratio 
Inner canthal distance (mm) 

WT	(n	=	13)	
22.9 ± 0.1 
10.4 ± 0.1 
0.46 ± 0.01 
6.1 ± 0.1 

L613V/+	(n	=	11)

21.4 ± 0.3A
10.9 ± 0.1A
0.51 ± 0.01A
6.5 ± 0.1A

Morphometric measurements from μCT scans of a cohort of 2-month-old 
mice (see Figure 2B for images). AP < 0.0001, 2-tailed Student’s t test.

phenotypic abnormalities in Raf1-mutant mice were reversed by 
postnatal MEK inhibitor treatment. Our results show that different 
NS genes have intrinsically distinct pathological effects and demon-
strate that enhanced MEK-ERK activity is critical for causing HCM 
and other RAF1-mutant NS phenotypes. Along with the companion 
study on LS-associated HCM by Marin et al. (60), these findings sug-
gest a mutation-specific approach to the treatment of RASopathies.

Results
Generation of L613V/+ mice. Expression of an activated Raf1 mutant 
during development might cause embryonic lethality. Therefore, 
in order to investigate the effects of the NS-associated, kinase-
activating RAF1L613V mutant, we designed an inducible knockin 
Raf1L613V allele (L613Vfl; Figure 1A). The targeting vector includ-
ed a cassette containing a splice acceptor sequence, a Raf1 cDNA 
fragment encoding WT exons 13–16, and a pGK-Neo (Neo) gene. 
The fusion cDNA/Neo cassette was flanked by loxP sites and was 
positioned upstream of exons 13–16 of the Raf1 gene itself, with an 
L613V mutation introduced into exon 16 and an HSV-TK cassette 
for negative selection. In the absence of Cre recombinase (Cre), Raf1 
exon 12 should be spliced to the cDNA (exon 13–16), leading to the 
production of WT Raf1. When Cre is present, the floxed cassette 
should be excised, evoking transcription of the mutant Raf1 allele.
The targeting construct was electroporated into G4 ES cells, 
and correctly targeted clones (L613Vfl/+) were identified by PCR 
and confirmed by Southern blotting (Figure 1B). We also validat-
ed the desired properties of the targeted locus in L613Vfl/+ ES 
cells (Figure 1C). As expected, expression of the mutant allele was 
undetectable by RT-PCR in the absence of Cre, but it was induced 
effectively upon introduction of a Cre expression vector (MSCV-
GFP-Cre). Mutant Raf1 protein was also expressed at levels compa-
rable to those of WT Raf1 (data not shown, but see Supplemental 
Figure 4; supplemental material available online with this article; 
doi:10.1172/JCI44929DS1). Chimeras were then generated by out-
bred morula aggregation, and germline transmission was obtained. 
L613Vfl/+ progeny were crossed to CMV-Cre mice, which express 
Cre ubiquitously, and then to WT mice, thereby generating mice 
with global Raf1L613V expression (referred to herein as L613V/+ 
mice) on a 129S6 × C57BL/6 mixed background.

L613V/+ mice were obtained at the expected Mendelian ratio at 
weaning, which indicated that on this mixed background, Raf1L613V 
expression during development is compatible with embryonic via-
bility. However, similar to mice expressing NS-associated Ptpn11 
mutant alleles (54), L613V/+ mice could not be obtained after 
backcrossing to C57BL/6 mice for more than 3 generations. Con-
sequently, all experiments herein were performed on the 129S6 × 
C57BL/6 mixed background.

L613V/+ mice show multiple NS phenotypes. L613V/+ newborns 
showed normal size at birth (data not shown). At weaning, however, 
male (Figure 2A) and female (data not shown) L613V/+ mice were 
significantly smaller than their WT littermates, and they remained 
shorter throughout their lives. Although their overall body pro-
portions were normal, L613V/+ mice exhibited facial dysmorphia  
(Figure 2B and Table 1). Consistent with their decreased body size, 
the skulls of L613V/+ mice were significantly shorter than those 
of WT mice. Their skull width was increased, however, resulting 
in a significantly greater width/length ratio. As a result, L613V/+ 
mice had a “triangular” facial appearance, with a blunter snout and 
widely set eyes (increased inner canthal distance). These features are 
reminiscent of the facial phenotype of mice expressing NS-associ-
ated Ptpn11 mutations (54, 57, 58) and represent the mouse equiva-
lent of the facial abnormalities seen in NS patients (61).

Like mouse models of Ptpn11 mutation–associated NS (54, 58) 
and many NS patients (62), L613V/+ mice had hematological 
defects. There was abnormal expansion of myeloid progenitors, 
and BM from L613V/+ mice yielded factor-independent myeloid 
colonies (Figure 2C). L613V/+ mice also developed splenomega-
ly, which became more severe as they aged (Figure 2D). Periph-
eral blood counts were normal at 4 months of age, but by 1 year, 
L613V/+ mice had developed subtle but statistically significant 
leukocytosis, neutrophilia, and monocytosis (Figure 2E) with nor-
mal hematocrit and platelet counts (data not shown).

L613V/+ mice show cardiac hypertrophy with chamber dilatation. 
Unlike PTPN11 alleles, which are negatively associated with 
HCM in NS patients (44) and in mouse models (54, 56, 58), 
RAF1 mutations that encode proteins with increased kinase 
activity are strongly associated with HCM (37, 38). Remark-
ably, L613V/+ mice showed evidence of cardiac hypertrophy as 
early as 2 weeks after birth, as indicated by an increased heart 
weight/BW ratio (Supplemental Figure 1A). Cardiac enlarge-
ment became even more obvious in adult L613V/+ mice, with 
histological analysis revealing substantial thickening of the ven-
tricular wall and septum (Figure 3A). Increased heart size can 
reflect a larger number of cardiomyocytes (e.g., as a consequence 
of excess proliferation during development) and/or cardiomyo-
cyte hypertrophy. Cardiomyocyte proliferation, as measured by 
BrdU incorporation assays, was comparable in E16.5 L613V/+ 
and WT embryos (Supplemental Figure 1B). By contrast, cross-
sectional area markedly increased — by about 35% — in cardio-
myocytes from 8-week-old L613V/+ compared with WT mice 
(Figure 3B), indicative of cardiac hypertrophy.

Cardiac hypertrophy can be secondary to pressure overload 
caused by stenotic valves or hypertension. Notably, mice express-
ing the NS-associated Ptpn11D61G mutation have severe valvulos-
eptal abnormalities, including atrial, atrioventricular, or ven-
tricular septal defects and double-outlet RV (54). In contrast, 
valvuloseptal development, as assessed by histology, appeared 
normal in 1-week-old L613V/+ mice (Supplemental Figure 1C 
and data not shown). Invasive hemodynamic studies established 
that ventricular pressure was actually lower in L613V/+ mice 
than in WT controls (see below).

To  assess  cardiac  morphology  and  function,  we  performed 
echocardiography on L613V/+ mice and littermate controls at 
2 and 4 months of age. As expected, LV diastolic posterior wall 
thickness (LVPWd) was increased in L613V/+ mice (Figure 3, C 
and D). Although chamber size was normal in 2-month-old mice, 
by 4 months, L613V/+ hearts showed an increase in LV internal 

1012	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 3      March 2011

Downloaded on October  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/44929

research article

Figure 3
L613V/+ mice show cardiac hypertrophy with chamber dilatation. (A) Representative gross appearance and H&E-stained cross-sections (origi-
nal magnification, ×4; scale bars: 2 mm) of WT (n = 25) and L613V/+ (n = 25) hearts at 8 weeks, as well as heart weight/BW ratio (HW/BW) of 
4-month-old WT and L613V/+ mice. (B) Cross-sections of cardiomyocytes (original magnification, ×400; scale bars: 100 μm). Cross-sectional 
area (numbers below) was measured in WGA-strained sections from 8 week-old mice (n = 5 samples per genotype, with 200 cells counted 
per sample using ImageJ). (C) Representative echocardiograms of hearts from 4-month-old mice. Arrows indicate LV diastolic dimension. (D) 
LVPWd at 2 and 4 months, measured by echocardiography. n = 13 (WT); 11 (L613V/+). (E) LVIDd and LVIDs of 2- and 4-month-old WT (n = 13)  
and L613V/+ (n = 11) hearts. (F) Cardiac contractility of 4-month-old WT (n = 13) and L613V/+ (n = 11) hearts, as measured by invasive hemody-
namic analysis. (G) Myh6 and Myh7 gene expression in 4-month-old WT (n = 6) and L613V/+ (n = 9) hearts, assessed by quantitative real-time 
PCR. (B, D, and E–G) *P < 0.05, **P < 0.005, ***P < 0.0001, 2-tailed Student’s t test.

end-diastolic dimension (LVIDd). LV internal end-systolic dimen-
sion (LVIDs) remained within normal limits (Figure 3, C and E), 
indicating preserved or enhanced function. Consistent with the 
latter interpretation, stroke volume (SV), ejection fraction (EF), 
fractional shortening (FS), and cardiac output (CO) were increased 
in L613V/+ mice (Table 2).

Invasive hemodynamic studies confirmed and extended these con-
clusions (Figure 3F and Table 3). L613V/+ mice showed increased 
dP/dtmax, consistent with enhanced contractility, but no change in 
cardiac relaxation (i.e., –dP/dt). Afterload (systolic pressure) was 
slightly lower in L613V/+ mice. Although this finding ruled out 
hypertension as a cause of hypertrophy in L613V/+ mice, it compli-
cated comparison of dP/dtmax values. For this reason, we also com-

pared dP/dt estimated at LV pressure (LVP) of 40 mm Hg (dP/dt@
LVP40), therefore reducing or eliminating the influence of afterload 
(63). Importantly, dP/dt@LVP40 was increased in L613V/+ animals 
(Figure 3F), providing conclusive evidence of increased contractility. 
Moreover, there was no pressure gradient across the aortic valves of 
L613V/+ mice (Table 3), ruling out aortic valve stenosis as a cause of 
their cardiac hypertrophy. Our finding of eccentric cardiac hyper-
trophy in the absence of pressure overload was consistent with the 
conclusion that L613V/+ mice have pathological hypertrophy.

Mice and humans with pathological hypertrophy often reactivate 
specific fetal genes (5, 6). There are 2 isoforms of cardiac myosin: 
α-MHC (faster kinetics; encoded by MYH6) and β-MHC (slower 
kinetics; encoded by MYH7). In rodents, Myh7 is expressed mainly in 

	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 3      March 2011 

1013

Downloaded on October  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/44929

research article

Table 2
Echocardiographic parameters in L613V/+ and WT mice at 2 and 
4 months of age

	

	
	
Heart rate (bpm) 
SV (μl) 
EF (%) 
FS (%) 
CO (ml/min) 

2	months	

4	months

WT	

L613V/+	
(n	=	13)	
(n	=	11)	
456 ± 19  454 ± 17 
49 ± 3A 
38 ± 1 
63 ± 2B 
56 ± 1 
34 ± 2A 
29 ± 1 
18 ± 1 
22 ± 2B 

WT	

L613V/+	
(n	=	12)	
(n	=	11)
485 ± 12  485 ± 22
57 ± 3C
40 ± 1 
63 ± 2A
54 ± 2 
34 ± 1C
28 ± 1 
19 ± 1 
 28 ± 2C

AP < 0.005, BP < 0.05, CP < 0.0001, 2-tailed Student’s t test.

late fetal life, whereas Myh6 is expressed predominantly in the adult. 
Reexpression of Myh7 and a shift from α-Mhc to β-Mhc is a marker 
for phenotypic reprogramming and HCM (5). Indeed, Myh6 mRNA 
levels decreased significantly in L613V/+ hearts, and there was a 
trend toward increased Myh7 expression (P = 0.09, 1-tailed Student’s 
t test; Figure 3G). Consequently, the Myh7/Myh6 ratio increased sig-
nificantly. Expression of Nppa (encoding Anp) and Nppb (encoding 
Bnp), 2 other fetal genes often associated with cardiac hypertrophy 
(5, 64), was unaffected in L613V/+ hearts (data not shown).

Enhanced hypertrophic response and functional decompensation in 
L613V/+ hearts following pressure overload. Although L613V/+ mice 
showed cardiac hypertrophy, they displayed enhanced cardiac 
function without signs of heart failure for at least a year of life. To 
gain further insight into the nature of the hypertrophy in L613V/+ 
mice, we assessed their response to biomechanical stress by trans-
verse aortic constriction (TAC). L613V/+ mice had an unusually 
high acute death rate after this procedure compared with controls 
(Figure 4A). Furthermore, the hearts of surviving L613V/+ mice 
showed dramatic ventricular, as well as left atrial, enlargement 
compared with WT mice (Figure 4B). Although WT mice had an 
approximately 45% increase in heart weight/BW ratio following 
TAC, L613V/+ mice had an approximately 72% increase. L613V/+ 
mice also developed more severe interstitial fibrosis (Figure 4C) 
and perivascular fibrosis (Figure 4D and Supplemental Figure 2A) 
after TAC. We excluded 2 L613V/+ mice from analysis: by 8 weeks 
of TAC, these mice had sustained a large spontaneous transmural 
infarct involving approximately 30% of the ventricular free wall, 
and extensive fibrosis with impaired systolic and diastolic func-
tion was evident (Supplemental Figure 2B).

These morphologic and histological findings established that 
L613V/+ mice have an altered response to pressure overload. Con-
sistent with this, TAC provoked increases in LVPWd in WT and 
L613V/+ mice; the increase was more pronounced in the L613V/+ 
mice (Figure 5A). LVIDd did not change after TAC in WT or L613V/+ 
mice, but remained elevated in the latter (Supplemental Figure 3A). 
Most importantly, several parameters of cardiac function, includ-
ing SV and FS, deteriorated in L613V/+ mice, whereas these were 
unaffected in WT mice (Figure 5B). There also was a trend toward 
decreased CO in L613V/+ mice subjected to TAC, although this 
did not reach statistical significance because these mice increased 
their heart rate sufficiently to compensate for decreased ventricular 
function (Supplemental Figure 3B). In addition, cardiac contrac-
tility (measured as either dP/dtmax or dP/dt@LVP40) decreased in 
L613V/+ mice, but not in WT mice (Figure 5C). Cardiac relaxation —  

as assessed by –dP/dt, normalized to mean arterial pressure (i.e., 
afterload) — was reduced comparably, whereas end-diastolic pres-
sure was increased to a similar extent in WT and L613V/+ mice  
(Figure 5C and Supplemental Figure 3C). Thus, while WT mice 
could adapt appropriately to pressure overload, L613V/+ mice 
exhibited substantial, occasionally fatal, functional decompensa-
tion with reductions in SV, FS, and dP/dtmax and dP/dt@LVP40, con-
sistent with early stages of heart failure by 8 weeks of TAC.

The Raf1L613V mutant increases Mek and Erk activation in response to 
multiple stimuli. Compared with WT RAF1, Raf1L613V has increased 
kinase activity in vitro and an enhanced ability to activate MEK-ERK 
in transfection studies (37, 38). We assessed the effect of Raf1L613V 
expressed at endogenous levels on the RAS-ERK pathway. Con-
sistent with the earlier overexpression experiments, Mek and Erk 
activation (as inferred from immunoblots with activation-specific 
antibodies) was enhanced in multiple cell types expressing Raf1L613V 
in response to a variety of stimuli, including LIF-stimulated ES cells 
(Supplemental Figure 4A) and EGF- or PDGF-stimulated mouse 
embryonic fibroblasts (MEFs; Supplemental Figure 4, B and C). Of 
direct relevance to the L613V/+ cardiac phenotype, Mek and Erk 
activation also were higher in L613V/+ than in WT neonatal cardio-
myocytes stimulated with receptor tyrosine kinase (heregulin-β1),  
cytokine receptor (IL-6), or GPCR (Ang II) agonists (Figure 6).  
Recently, cardiac fibroblasts were implicated in the genesis of car-
diac hypertrophy (65, 66); notably, L613V/+ cardiac fibroblasts also 
showed enhanced agonist-stimulated Mek-Erk activation (Figure 7). 
Both the quantitative and the qualitative effects of the mutant Raf1 
allele on Mek and Erk activation differed in cardiomyocytes versus 
cardiac fibroblasts (or MEFs) and in response to different stimuli. In 
some cases, mutant Raf1 affected only the magnitude of activation, 
in others, solely the duration of activation, and for still others, both 
magnitude and duration. Such differences might reflect distinct 
feedback responses to the agonists in various cell types.

Although it was difficult to detect Erk activation in the adult 
heart under basal conditions (data not shown), basal Mek activ-
ity was significantly higher in adult L613V/+ compared with WT 
hearts (Figure 8A). To compare Mek and Erk activation in vivo, we 
monitored the response of WT and L613V/+ mice to pressure over-
load evoked by TAC for up to 45 minutes. Mek activation remained 
significantly higher in L613V/+ hearts throughout the period of 
acute TAC (Figure 8A). Erk activation was significantly higher in 
L613V/+ hearts after 30 minutes of TAC compared with WT hearts, 
but was similar to WT at other time points (Figure 8B).

Table 3
Additional hemodynamic parameters of hearts from 4-month-old 
mice

	
Heart rate (bpm) 
LVP (mmHg) 
EDP (mmHg) 
Systolic pressure (mmHg) 
Diastolic pressure (mmHg) 
–dP/dt (mmHg/s) 
–dP/dt/MAP (1/s) 

WT	(n	=	12)	
516 ± 17 
121 ± 3 
4.1 ± 0.7 
117 ± 3 
83 ± 3 

L613V/+	(n	=	12)

521 ± 17
113 ± 2A
3.9 ± 0.5
109 ± 2
77 ± 2

–11,010 ± 332 

–118 ± 4 

–11,190 ± 327

–127 ± 3

Cardiac catheterizations were performed and analyzed as described in 
Methods. EDP, end-diastolic pressure; MAP, mean arterial pressure.  
AP < 0.05, 2-tailed Student’s t test.

1014	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 3      March 2011

Downloaded on October  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/44929

research article

Figure 4
Abnormal response of L613V/+ mice to pressure overload. (A) Survival curves of WT (n = 25) and L613V/+ (n = 24) mice after TAC. **P < 0.005, 
log-rank test. (B) Gross appearance of hearts and heart weight/BW ratio at 8 weeks after TAC or sham surgery. Dashed outlines demonstrate 
markedly enlarged left atrium in L613V/+ compared with WT mice. **P < 0.005, ***P < 0.0001, Bonferroni post-test when ANOVA was significant; 
##P < 0.005, 1-tailed Student’s t test. (C) Severe interstitial fibrosis in L613V/+ hearts (PSR staining; original magnification, ×100) at 8 weeks after 
TAC. Percent pixels staining positive with PSR for interstitial fibrosis was quantified using ImageJ. n = 14 (WT); 13 (L613V/+). ***P < 0.0001, 
Bonferroni post-test when ANOVA was significant; #P < 0.05, 2-tailed Student’s t test. (D) Perivascular fibrosis in hearts (PSR staining; original 
magnification, ×200) at 8 weeks after TAC. Similar results were obtained when Masson Trichrome stain was used to assess fibrosis.

We also assayed several signaling pathways implicated in other 
models of cardiac hypertrophy/HCM by immunoblotting with 
appropriate phosphospecific antibodies. Activation of the MAPK 
family members JNK and p38 was comparable in Ang II–stimu-
lated neonatal cardiomyocytes and EGF-stimulated cardiac fibro-
blasts (Supplemental Figure 5, A and B). Likewise, Akt, GSK-3β, 
and p70S6K activation in response to the agonists tested were 
unaffected by Raf1L613V expression in either cell type (Supplemen-
tal Figure 5, A and B). Importantly, in the same experiments, Mek 
and Erk activation were enhanced in L613V/+ cardiomyocytes 
and cardiac fibroblasts.

MEK inhibitor treatment normalizes NS phenotypes in L613V/+ mice. 
The genetics of NS and other RASopathies and the ability of 
Raf1L613V to selectively enhance Mek and Erk activation by mul-
tiple agonists in cardiomyocytes and cardiac fibroblasts strongly 
implicate enhanced Mek-Erk activation in the pathogenesis of 
NS phenotypes, including HCM. We asked whether any of these 
phenotypes could be reversed if Mek-Erk activation was normal-
ized by treatment of L613V/+ mice with a MEK inhibitor. In initial 

experiments, the ATP-uncompetitive inhibitor PD0325901 (67) 
or empty vehicle was injected i.p. daily to WT and L613V/+ mice 
(5 mg/kg BW), beginning at 4 weeks and continuing for the suc-
ceeding 6 weeks. Importantly, at the start of the treatment period, 
L613V/+ mice already showed substantial growth defects, facial 
dysmorphia, and cardiac hypertrophy.

Remarkably, the body length of L613V/+ mice began to catch 
up  with  WT  mice  after  1  week  of  treatment,  and  by  2  weeks, 
PD0325901-treated  L613V/+  mice  were  the  same  length  as 
untreated WT mice (Figure 9A). PD0325901-treated WT mice also 
increased their body length such that by the last 2 weeks of treat-
ment, they were significantly longer than control, untreated WT 
mice. Notably, however, PD0325901-treated L613V/+ mice achieved 
the same final body length as did treated WT mice, which argues 
that increased Mek-Erk activity is the primary cause of the growth 
defect in L613V/+ mice (see Discussion). Inhibitor treatment also 
increased the BW of L613V/+ mice, but surprisingly, they — as 
well as treated WT mice — gained substantially more BW than did 
untreated WT mice (Figure 9B). Increased BW in PD0325901-treat-

	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 3      March 2011 

1015

Downloaded on October  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/44929

research article

Figure 5
Echocardiographic and hemodynamic parameters in WT and L613V/+ mice following pressure overload. (A) LVPWd at 8 weeks after TAC or 
sham surgery. (B) Decreased SV and FS in L613V/+ mice after TAC. (C) Decreased cardiac contractility in L613V/+ mice after TAC. Because 
LVPs were not identical in WT and L613V/+ mice (see Table 3), both dP/dtmax and dP/dt@LVP40 are shown. *P < 0.05, **P < 0.005, ***P < 0.0001,  
Bonferroni post-test when ANOVA was significant; ##P < 0.005, ###P < 0.0001, 1-tailed Student’s t test. n = 12 (WT sham); 11 (L613V/+ sham); 
22 (WT TAC); 13 (L613V/+ TAC).

ed mice was accompanied (and, presumably, in large part caused) 
by an obvious increase in body fat (data not shown); thus, increased 
adiposity/body mass was an unanticipated, and to our knowledge 
previously unreported, side effect of PD0325901 treatment (and 
possibly MEK inhibitor treatment in general; see Discussion).

PD0325901 treatment also affected the L613V/+ cardiac pheno-
type. The heart weight/BW ratio in L613V/+ mice was restored to 
normal range (i.e., WT control) after treatment, whereas there was 
no significant change in treated WT mice (Figure 9C). Echocardiog-
raphy (Figure 9, D and E) and invasive hemodynamic (Figure 10)  
studies showed significant improvement in multiple parameters 
of cardiac morphology and function. Furthermore, histological 
assessment of cross-sectional area of cardiomyocytes confirmed 
the normalization of cardiomyocyte size in L613V/+ mice after 
treatment (Figure 9F). The significant increase in body size and 
body mass caused by PD0325901 treatment potentially compli-
cates echocardiographic and invasive hemodynamic comparisons 
of WT and L613V/+ mice before and after treatment. Therefore, 
we compared all parameters using both nominal values and values 
normalized by cube root of BW (BW1/3) (Supplemental Figure 6); 
overall, the 2 analyses led to similar conclusions. First, there was a 
significant reduction (toward normal) in LVPWd in L613V/+ mice 

after treatment (Figure 9D); this difference was even more signifi-
cant when normalized by BW1/3 (Supplemental Figure 6A). Nomi-
nal LVIDd was unchanged in PD0325901-treated L613V/+ mice 
(Figure 9E), although when this value was normalized, chamber 
dilatation improved significantly, becoming comparable to that of 
WT controls (Supplemental Figure 6B). Inhibitor treatment clearly 
reduced the abnormal SV and FS in L613V/+ mice toward normal 
levels (i.e., untreated or treated WT; Figure 10A and Supplemental 
Figure 6C). There also was a strong trend toward decreased CO 
in L613V/+ mice after PD0325901 treatment (Figure 10A and 
Supplemental Figure 6D). Finally, the excessive cardiac contrac-
tility (dP/dt and dP/dt@LVP40) in L613V/+ mice was ameliorated 
by PD0325901 treatment, whereas cardiac relaxation remained 
unchanged (Figure 10B).

PD0325901 treatment did not improve the facial dysmorphia in 
L613V/+ mice in the above study, most likely because skull devel-
opment had already been completed by the onset of drug adminis-
tration. We tested whether earlier, but still postnatal, MEK inhibi-
tor treatment could prevent or ameliorate L613V/+ facial defects. 
Lactating female mice were injected i.p. with PD0325901 (5 mg/kg  
BW) daily, beginning at P0 until weaning at P21. Weaned mice 
were then injected individually with the same dose of PD0325901 

1016	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 3      March 2011

Downloaded on October  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/44929

research article

Figure 6
Raf1L613V mutant increases Mek and Erk activation in cardiomyocytes. Cardiomyocytes prepared from neonatal WT and L613V/+ mice were 
starved for 24 hours and then stimulated for the indicated number of minutes with 1 μg/ml Ang II (A), 10 ng/ml IL-6 (B), and 100 ng/ml heregulin-β1  
(C). Cell lysates (15 μg protein) were immunoblotted with the indicated antibodies. Quantification of blots is also shown. 1 of 2 experiments with 
comparable results is shown.

for another 5 weeks. As expected from our initial treatment regi-
men (Figure 9A), the growth defect in L613V/+ mice was again pre-
vented (data not shown). Remarkably, however, earlier PD0325901 
treatment had a dramatic effect on the appearance of L613V/+ 
mice: they no longer had triangular faces, instead appearing indis-
tinguishable from treated or untreated WT controls (Figure 11A). 
μCT morphometry confirmed that inner canthal distance was 
reduced significantly, skull length increased, and skull width and 
width/length ratio decreased in PD0325901-treated L613V/+ mice 
(Figure 11B); all values were indistinguishable from those of treat-
ed or untreated WT mice by the end of the treatment period.

Discussion
We describe here a knockin mouse model for NS caused by a 
Raf1 gain-of-function mutation. Similar to mouse models of 
Ptpn11 mutation–associated NS, Raf1L613V heterozygosity caused 
proportional short stature, facial dysmorphia, and hematologi-
cal defects. Unlike phosphatase-activating Ptpn11 alleles, which 
cause valvuloseptal abnormalities (54, 55, 58), L613V/+ mice 
had normal valvuloseptal development and instead exhibited 
eccentric cardiac hypertrophy that decompensated upon pres-
sure overload. Agonist-evoked Mek-Erk activation was enhanced 
in multiple cell types without changes in several other signaling 
pathways implicated in cardiac hypertrophy/HCM. Remarkably, 
postnatal MEK inhibition normalized the growth, facial, and 
cardiac defects in L613V/+ mice, demonstrating that continued 

MEK-ERK activity is critical for causing HCM and other NS phe-
notypes and identified MEK inhibitors as potential therapeutic 
agents for the treatment of NS.

RASopathies are a class of human genetic syndromes caused 
by germline mutations in genes that encode components of the 
RAS-ERK pathway (31, 32). Not surprisingly, these disorders share 
several features, albeit with varying degrees of penetrance, yet each 
also exhibits unique and characteristic phenotypes. Conceivably, 
the specific mutant gene, possibly as a consequence of its position 
in the pathway and susceptibility to feedback regulation, could 
direct the phenotype. Alternatively, genetic modifiers in the highly 
outbred human population could be determinative.

Previous mouse models suggest that both the gene and the 
genetic background are important to the ultimate RASopathy phe-
notype. Clearly, different mutations in the same RASopathy gene 
can result in distinguishable phenotypes: gain-of-function Ptpn11 
mutations, depending on the degree of their phosphatase activity, 
cause a variable spectrum of NS phenotypes (54, 55, 58). The cur-
rent study, along with a parallel analysis of knockin mice express-
ing a NS-associated Sos1E846K mutant (68), shows that mutations in 
different genes that cause the same RASopathy syndrome yield dif-
ferent phenotypes: mice with phosphatase-activating Ptpn11 muta-
tions have valvuloseptal defects, but not HCM (54, 55); Sos1E846K/+  
mice develop LV hypertrophy with incompletely penetrant aortic 
stenosis; and L613V/+ mice exhibited HCM with normal valvulo-
septal development.

	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 3      March 2011 

1017

Downloaded on October  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/44929

research article

Figure 7
Raf1L613V mutant increases Mek and Erk activation in cardiac fibroblasts. Cardiac fibroblasts prepared from neonatal WT and L613V/+ mice were 
starved for 16 hours and then stimulated for the indicated number of minutes with 50 ng/ml EGF (A), 100 ng/ml IGF-I (B), 100 ng/ml PDGF (C), 
and 50 ng/ml FGF2 (D). Cell lysates (20 μg protein) were immunoblotted with the indicated antibodies. Quantification of blots is also shown.  
1 of 2 experiments with comparable results is shown.

On the other hand, mutations associated with different RASopa-
thies also have distinct effects in mice. In contrast to the NS mice 
discussed above, an HRasG12V knockin mouse model of CS shows 
abnormal cranial dimensions, papillomas, and angiosarcomas. 
These mice have cardiac hypertrophy, but also aortic stenosis, 
making it unclear whether the hypertrophy is primary or second-
ary (32, 59). As described in the companion paper by Marin et al. 
(60), a mouse model of LS caused by Ptpn11Y279C indicates that, 
unlike Ptpn11 alleles with increased catalytic activity, catalytically 
impaired mutants develop HCM and skeletal abnormalities as well 
as short stature and facial dysmorphia.

While the specific mutation plays a major role in determining 
RASopathy phenotype, modifier loci also clearly contribute: just 
as there is considerable phenotypic variation between family mem-
bers carrying the same NS or LS allele (69), there are differences 
in disease spectrum and severity of mice with Ptpn11 (54, 58) and 
Raf1 (data not shown) mutations on different strain backgrounds. 
Ptpn11D61G/+ mice show incomplete penetrance of valvuloseptal 
defects on mixed background and various penetrance of embry-

onic lethality on different strain backgrounds (54, 58). L613V/+ 
mice were obtained at the expected Mendelian ratio on mixed 
background, whereas on the C57BL/6 background, this mutant 
allele almost always was lethal (data not shown). All of these data 
suggest that incomplete penetrance reflects strain-specific modi-
fiers. Genomic scans using SNP panels should help to determine 
whether cloneable modifiers exist or whether heterosis accounts 
for the variable penetrance.

The role of the RAS-ERK pathway in cardiac hypertrophy has been 
controversial. Overexpression of MAPK phosphatase 1 (MKP-1)  
blocks both agonist-induced hypertrophy in vitro and pressure 
overload–associated hypertrophy in vivo (70). However, MKP-1  
inactivates all 3 major MAPKs, so the study could not address 
the specific effects of Ras-Erk pathway activation. Depletion of 
ERK1/2 with antisense oligonucleotides or pharmacological inhi-
bition of MEK1/2 attenuates the hypertrophic response to ago-
nist stimulation of cultured cardiomyocytes (23, 24), consistent 
with a requirement for MEK-ERK activation in the hypertrophic 
response. Transgenic mice with cardiac-specific expression of 

1018	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 3      March 2011

Downloaded on October  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/44929

research article

Figure 8
Enhanced Mek and Erk activation in L613V/+ hearts after pressure overload. Hearts from WT and L613V/+ mice were subjected to TAC for the 
indicated number of minutes (n = 5 per group per time point), then lysed and analyzed by immunoblotting with the indicated antibodies. Erk2 
levels are shown as a loading control. Each lane represents an individual animal; quantification of all samples is also shown. (A) Mek activation, 
with all samples from a single time point analyzed on the same gel. (B) Representative samples of Erk activation from each time point analyzed 
on the same gel. (A and B) *P < 0.05, 2-tailed Student’s t test.

HRasG12V display HCM associated with interstitial fibrosis and 
sudden death (20–22). Cardiac-specific Nf1-deleted mice develop 
marked cardiac hypertrophy, progressive cardiomyopathy, and 
fibrosis as adults (71).

Conversely, other studies suggest that MEK-ERK activity is 
dispensable for cardiomyocyte hypertrophy. Transgenic mice 
with cardiac-restricted expression of activated Mek1 exhibit 
concentric hypertrophy without signs of cardiomyopathy (26). 
Although hypertrophy in this model was interpreted as physi-
ological, these mice also have impaired diastolic function and 
reactivated cardiac fetal gene expression, which is more con-
sistent with pathological hypertrophy. A recent study showed 
that Erk1–/–Erk2+/– mice or transgenic mice with cardiac-specific 
expression of Dusp6, an Erk1/2-specific phosphatase, showed 
a normal hypertrophic response to pressure overload and exer-
cise (27). In both of these lines of mice, however, residual Erk 
activity cannot be excluded. Also, it is possible that Dusp6 has 
other targets besides Erk1/2, which could complicate interpre-
tation of these results. Moreover, most of these earlier studies 
involved cardiomyocyte-specific expression or deletion of poten-
tial hypertrophy-related genes, which excludes the potential 
contribution of other cell types in the heart to the hypertrophic 
response. Recent studies show that cardiac fibroblasts play key 
roles in myocardial development and function (72, 73). Embry-
onic cardiac fibroblasts induce myocyte proliferation, whereas 
adult cardiac fibroblasts promote myocyte hypertrophy (72) and 
evoke pathological hypertrophy and fibrosis in response to dis-
ease stimuli (65, 66). Of particular note, enhanced Ras-Erk acti-

vation in cardiac fibroblasts is implicated in pathological hyper-
trophy and fibrosis caused by overexpression of the β-adrenergic 
receptor in cardiomyocytes (66).

Our mouse model, in which a NS-associated Raf1 mutant was 
expressed globally under normal promoter control, supports the 
conclusion that excessive Ras-Erk pathway activity causes HCM. Sev-
eral lines of evidence indicated that L613V/+ mice have pathological 
cardiac hypertrophy. Hypertrophy was eccentric in these mice, and 
they showed the characteristic shift from Myh6 to Myh7 expression 
seen in pathological hypertrophy. In response to pressure overload 
by TAC, they had an unusually high death rate, presumably due to 
inability to adapt to this stress or arrhythmia, while surviving mice 
showed clear evidence of functional decompensation. Importantly, 
in our model, unlike many previous studies (see above), the mutant 
allele was expressed in both cardiomyocytes and cardiac fibroblasts, 
as well as multiple other cell types. Moreover, Mek-Erk activation 
was enhanced in response to multiple agonists in these cells. It will 
be important to determine whether mutant expression in cardiomy-
ocytes, cardiac fibroblasts, or both is important for HCM in L613V/+ 
mice; our inducible Raf1 allele should facilitate such analyses. Most 
importantly, postnatal MEK inhibitor treatment substantially nor-
malized the cardiac defects in L613V/+ mice, providing strong evi-
dence for the critical role of the RAS-ERK pathway in initiating and 
maintaining the cardiac hypertrophic response.

Postnatal MEK inhibitor treatment also normalized the growth 
defects and, if administered early enough, the facial dysmorphia in 
L613V/+ mice. Notably, MEK inhibitor treatment also increased 
the body length of WT mice, but there was no difference between 

	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 3      March 2011 

1019

Downloaded on October  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/44929

research article

Figure 9
MEK inhibitor treatment rescues growth defect and cardiac hypertrophy in L613V/+ mice. Mice were injected i.p. daily with PD0325901 (PD;  
5 mg/kg BW) or vehicle, starting at 4 weeks of age and for the succeeding 6 weeks. Body length (A) and BW (B) were measured weekly. Note 
the rapid normalization of body length, as well as the increase in BW caused by inhibitor treatment. #P < 0.05, ##P < 0.005, ###P < 0.0001, 2-way 
repeated-measures ANOVA; *P < 0.05, **P < 0.005, ***P < 0.0001, Bonferroni post-test when ANOVA was significant (black symbols, WT PD 
vs. WT control; red symbols, L613V/+ PD vs. L613V/+ control). (C) Heart weight/BW ratio and (D) LVPWd were restored to within normal limits 
in inhibitor-treated mice. **P < 0.005, ***P < 0.0001, Bonferroni post-test when ANOVA was significant; #P < 0.05, 1-tailed Student’s t test. (E) 
LVIDd. **P < 0.005, Bonferroni post-test when ANOVA was significant; #P < 0.05, ##P < 0.005, 1-tailed Student’s t test. n = 14 (WT); 10 (L613V/+); 
6 (WT PD); 14 (L613V/+ PD). (F) Cross-sectional area of cardiomyocytes (original magnification, ×400; scale bar, 100 μm), measured in WGA-
strained heart sections (n = 2 samples per group, with 200 cells counted per sample using ImageJ). ***P < 0.0001, Bonferroni post-test when 
ANOVA was significant. See also Supplemental Figure 6.

the mutant and WT treated groups in terms of final body length 
after treatment. Likewise, MEK inhibitor treatment at doses that 
effectively normalized L613V/+ cardiac anatomy and function had 
little effect on cardiac function in WT mice. These results strongly 
suggest that all of these NS phenotypes are caused by excessive 
MEK-ERK activity, as opposed to the MEK inhibitor acting on a 
parallel pathway to mitigate syndromic features.

Unexpectedly, we found that PD0325901 treatment caused a 
significant increase in BW with an obvious increase in body fat. 
Although we cannot exclude the possibility that this is an idiosyn-

cratic (i.e., off-target) effect of this specific MEK inhibitor, other evi-
dence points to a potential obesity-promoting effect of MEK-ERK 
inhibition. For example, leptin activates Erk via an Shp2-dependent 
pathway (74, 75), and deletion of Shp2 in postmitotic forebrain neu-
rons causes early-onset obesity with decreased ERK activation and 
evidence of leptin resistance (76). We suspect that MEK inhibition 
may act in analogous ways to promote obesity in our mice.

In summary, our data demonstrate a critical role of the RAS-
ERK pathway in the genesis of HCM in NS and show that NS 
phenotypes can be rescued by pharmacological inhibition of 

1020	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 3      March 2011

Downloaded on October  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/44929

research article

Figure 10
MEK inhibitor treatment normalizes cardiac function in L613V/+ mice. (A) Echocardiographic parameters of hearts after treatment with 
PD0325901 as described in Figure 9. Note normalization of SV and FS, with a trend toward CO normalization. *P < 0.05, **P < 0.005,  
***P < 0.0001, Bonferroni post-test when ANOVA was significant; #P < 0.05, 1-tailed Student’s t test. (B) Hemodynamic parameters, assessed by 
cardiac catheterization, after PD0325901 treatment. For calculating statistical significance, significant outliers (circled data points), as assessed 
by Grubbs test, were removed. *P < 0.05, Bonferroni post-test when ANOVA was significant (P = 0.09 including outliers); #P < 0.05, 1-tailed 
Student’s t test (P = 0.12 including outliers). n = 14 (WT); 10 (L613V/+); 6 (WT PD); 14 (L613V/+ PD).

MEK1/2.  Previous  studies  showed  that  genetic  ablation  of 
Erk1/2 (55, 58) or prenatal treatment with a MEK inhibitor  
(57, 68) can prevent some NS phenotypes. Although these stud-
ies provided evidence for the key role of Mek-Erk hyperactivity 
in NS pathogenesis, they did not resolve whether MEK inhibi-
tion can reverse these phenotypes. Conversely, our results sug-
gest that MEK inhibition may be useful for the specific treat-
ment of Raf1 mutant NS, and possibly for other RASopathies 
associated with increased MEK-ERK pathway activity. Interest-
ingly, the companion paper by Marin et al. shows that LS-asso-
ciated HCM is associated with hyperactivation of the PI3K-Akt 
pathway and can be rescued by rapamycin treatment (60). Taken 
together, these studies argue for a mutation-specific, personal-
ized approach to RASopathy therapy.

Methods
Generation of L613V/+ mice. To construct the targeting vector for our 
inducible Raf1L613V knockin mice, a short arm containing Raf1 exon 12 
(SacII-NotI genomic fragment) and a long arm including exons 13–16 
(BamHI-ClaI genomic fragment) were ligated into the vector pGK Neo-
HSV-1 TK (77). The L613V (exon 16) mutation, marked by a unique 
DraIII site, was introduced by site-directed mutagenesis. A splice accep-
tor sequence, a Raf1 cDNA fragment encoding wild-type exons 13–16, 

and a pGK-Neo (Neo) gene were positioned after the first loxP site as 
a SalI-XbaI fragment. The targeting vector was linearized with SacII 
and electroporated into G4 ES cells (129S6 × C57BL/6 F1 background). 
Genomic DNA, isolated from doubly G418/1-resistant and (2-deoxy-2-
fluoro-β-D-arabinofuranosyl)-5 iodouracil–resistant (FIAU-resistant) 
ES clones (positive and negative selection, respectively), was screened 
by PCR using primers outside and inside the targeting vector (Supple-
mental Table 1), followed by NotI digestion, which marks the targeting 
vector. Homologous recombinants were confirmed by Southern blotting 
using Neo and external (5′ and 3′) probes (Supplemental Table 1). For 
these experiments, genomic DNA was digested with XbaI (5′ and Neo 
probes) or BamHI (3′ probe).

To validate the desired properties of the targeted locus, correctly tar-
geted ES cells were transfected with a Cre-expressing plasmid (MSCV-
GFP-Cre) to excise the cDNA-Neo cassette (see below). Expression of 
Raf1L613V mRNA was confirmed by RT-PCR (Supplemental Table 1), fol-
lowed by digestion with DraIII, which marks the L613V allele. Chime-
ras were generated by outbred morula aggregation (Toronto Centre of 
Phenogenomics), and germline transmission was obtained (L613Vfl/+ 
mice). L613Vfl/+ mice (129Sv × C57BL/B6) were crossed to CMV-Cre 
(C57BL/B6) mice, which express Cre ubiquitously, and then to WT 
(129S6) mice to generate mice with global Raf1L613V expression (L613V/+ 
mice; 129Sv × C57BL/B6). Mice on a 129Sv × C57BL/B6 mixed back-

	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 3      March 2011 

1021

Downloaded on October  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/44929

research article

For biochemical studies, ES cells were removed 
from feeders, starved in knockout DMEM con-
taining 1% FBS for 6 hours, and then stimulated 
with 103 U/ml LIF before harvesting.

Primary  MEFs  were  prepared  from  E13.5 
embryos and cultured in DMEM (Invitrogen) 
containing 10% FBS and 100 U/ml penicillin/
streptomycin (Invitrogen), as described previous-
ly (78). MEFs were starved in serum-free DMEM 
for 16 hours before stimulation, and then stim-
ulated with 10 ng/ml EGF or 50 ng/ml PDGF 
(both from PeproTech) before harvesting.

Neonatal mouse ventricular myocytes (neo-
natal  cardiomyocytes)  were  isolated  using 
methods adapted from a previous study (79). 
In brief, 1-day-old mouse hearts were harvest-
ed and predigested with 0.15 mg/ml trypsin 
(Invitrogen) at 4°C for 12–16 hours, followed 
by 50 U/ml type II collagenase (Worthington 
Biochemical) and 0.2 mg/ml trypsin in calcium- 
and bicarbonate-free Hanks buffer with HEPES 
for 1–2 hours at 37°C. Noncardiomyocytes were 
depleted by differential plating for 1 hour. Car-
diomyocytes were counted, seeded at 2.5 × 105  
cells/ml  on  Falcon  Primaria  tissue-culture 
plates (BD Biosciences), and cultured at 37°C 
in DMEM/Ham’s F12 (1:1 [v/v]; Invitrogen), 
10% FBS, and 100 U/ml penicillin/streptomy-
cin (Invitrogen) supplemented with 0.1 mM 
bromodeoxyuridine (Sigma-Aldrich) and 20 μM 
arabinosylcytosine (Sigma-Aldrich) to inhibit 
rapidly proliferating cells. After 24 hours, this 
medium was replaced with serum-free DMEM/
Ham’s F12 (1:1) medium supplemented with 
1% insulin-transferrin-selenium supplements-X  
(Invitrogen). After an additional 24 hours, car-
diomyocytes were stimulated with 10 ng/ml  
IL-6  (PeproTech),  100  ng/ml  heregulin-β1 
(PeproTech), or 1 μg/ml Ang II (Sigma-Aldrich) 
before harvesting.

Noncardiomyocytes from the above prepara-
tion, mainly cardiac fibroblasts, were cultured 
in DMEM containing 10% FBS and 100 U/ml 
penicillin/streptomycin. Cardiac fibroblasts were 
starved in serum-free DMEM for 16 hours, and 
then stimulated with EGF (50 ng/ml), IGF-I (100 ng/ml), PDGF (100 ng/ml),  
or FGF2 (100 ng/ml), all from PeproTech, before harvesting.

Body size analysis and morphometry. For growth curves, body length (anal-
nasal length) and BW were measured weekly. For skeletal morphometry, 
mice were anesthetized with 2% isoflurane and scanned using a Locus Ultra 
μCT scanner (GE Healthcare). 3D images of the skeleton were generated 
and analyzed with GEHC MicroView software (GE Healthcare). Skull mea-
surements were made according to Jackson Laboratory standard protocols 
and procedures (http://craniofacial.jax.org/standard_protocols.html).

Histology, immunohistochemistry, and BrdU incorporation assays. Hearts 
for morphometry and histochemistry were fixed in the relaxed state by 
infusion of 1% KCl in PBS, followed by 10% buffered formalin. Hearts 
were then incubated in 10% buffered formalin overnight and embedded 
in paraffin. Sections (5 μm) were prepared and stained with H&E, pic-
rosirius red (PSR), or Masson Trichrome. Cell membranes were stained 

Figure 11
Early  postnatal  MEK  inhibitor  treatment  rescues  facial  dysmorphia  in  L613V/+  mice. 
Lactating female mice were injected i.p. daily with PD0325901 (5 mg/kg BW) or vehicle, 
starting at P0 until weaning at P21. Weaned mice were then injected i.p. individually with 
PD0325901 (5 mg/kg BW) or vehicle daily for another 5 weeks. (A) Gross facial appearance. 
(B) Morphometric measurements of skulls from μCT scans. ICD, inner canthal distance.  
**P < 0.005, ***P < 0.0001, Bonferroni post-test when ANOVA was significant. n = 11 (WT); 
10 (L613V/+); 6 (WT PD); 7 (L613V/+ PD).

ground were used for all experiments. For genotyping, genomic DNA 
was prepared from tails, then subjected to PCR (Supplemental Table 1) 
and digestion with DraIII.

All animal studies were approved by the University Health Network Ani-
mal Care Committee (Toronto, Ontario, Canada) and performed in accor-
dance with the standards of the Canadian Council on Animal Care.

Cell culture. ES cells were cultured on γ-irradiated MEF feeders in knock-
out DMEM (Invitrogen), containing 15% ES-tested (HyClone, Thermo Sci-
entific) FBS, 2 mM l-glutamine (Invitrogen), 0.1 mM nonessential amino 
acids (Invitrogen), 0.1 mM β-mercaptoethanol (Sigma-Aldrich), 100 U/ml 
penicillin/streptomycin (Invitrogen), and 500 U/ml LIF (ESGRO, Chemi-
con). ES cells were transfected with MSCV-GFP-Cre plasmid using Lipo-
fectamine 2000 reagent (Invitrogen) according to the manufacturer’s 
protocol. GFP-positive cells were purified by fluorescence-activated cell 
sorting (FACS) at 48 hours after transfection and used for RNA isolation. 

1022	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 3      March 2011

Downloaded on October  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/44929

research article

with FITC-conjugated wheat germ agglutinin (WGA; Sigma-Aldrich) 
according to the manufacturer’s protocol. Nuclei were stained with 
DAPI. Cross-sectional area of cardiomyocytes with centrally located 
nuclei (to ensure the same plane of sectioning) was measured by using 
ImageJ. 5 individual samples were analyzed per genotype, with 200 cells 
measured in each.

For proliferation assays, pregnant mice (E16.5) were injected i.p. with 
BrdU (100 μg/g BW) 1 hour before sacrifice. Embryos were fixed in 10% 
buffered formalin overnight and embedded in paraffin. BrdU incorpora-
tion was detected using rat anti-BrdU primary antibody (1:50; Abcam). 
Immune complexes were visualized using F(ab)2 biotin-conjugated donkey 
anti-rat IgG (1:500; Research Diagnostics Inc.) and the Vectastain Elite ABC 
Kit (Vector Laboratories). Sections were counterstained with hematoxylin. 
For each sample, BrdU+ cells were counted in 10 randomly selected fields.
Hematopoietic analysis. Myeloid colony assays (in the absence of added 
cytokines) were performed as described previously (80). In brief, BM 
cells were suspended in MethoCult M3234 without cytokines (Stem Cell 
Technologies) at 105 cells/ml, and colonies were scored after 7–9 days. 
Complete blood counts were determined by using a Hemavet 850FS 
(Drew Scientific).

Echocardiographic and hemodynamic measurements. For echocardiography 
and cardiac catheterization, mice were anesthetized with isoflurane/oxy-
gen (2%:100%), and body temperature was maintained at approximately 
37.5°C. Transthoracic 2D and M-mode echocardiography was performed 
from the long axis view of the heart at the level of the papillary muscle 
with a Visualsonics Vevo 770 imaging system (Visualsonics) equipped 
with a 30-MHz linear transducer (RMV707B). Measurements of LVIDs, 
LVIDd, and LVPWd were made under Time Motion-mode (TM-mode). 
The  papillary  muscles  were  excluded  from  all  measurements.  Mea-
surements were averaged from at least 3 separate cardiac cycles. From 
TM-mode measurements, end-diastolic volume (EDV) was calculated 
as (4.5 × normalized LVIDd2); end-systolic volume (ESV) was calcu-
lated as (3.72 × normalized LDIVs2); SV was calculated as EDV — ESV;  
CO was calculated as SV × heart rate; FS percentage was calculated as 
(LVIDd – LVIDs)/LVIDd × 100; and EF percentage was calculated as 
(EDV – ESV)/EDV × 100.

For invasive hemodynamic assessments, a 1.2F catheter (model no. FTS-
1211B-0018; Scisense Inc.) was inserted via the right carotid artery into the 
LV. Hemodynamic signals were digitized at a sampling rate of 1 kHz and 
recorded by computer using the MP100 imaging system and Acqknowl-
edge software (BIOPAC Systems Inc). Following recording of LV pressure, 
the catheter was relocated to the ascending aortic for measurement of aor-
tic blood pressure. Mean arterial pressure was calculated as (systolic pres-
sure + diastolic pressure × 2)/3.

TAC. 8- to 9-week-old male mice (25–30 g BW) were anesthetized with 2% 
isoflurane, intubated, connected to a ventilator (Harvard Apparatus), and 
ventilated at a tidal volume of approximately 230 μl and 135 breaths/min. A 
parasternal thoracotomy was performed to expose the transverse aorta, which 
was then constricted with a 7/0 silk suture tied around a 27-gauge needle. 
Pressure overload was maintained for various times as indicated in Results 
and the figure legends.

MEK inhibitor treatment. N-([R]-2,3-dihydroxy-propoxy)-3,4-difluoro-2-
(2-fluoro-4-iodo-phenylamino)-benzamide (PD0325901) was synthesized 
according to the disclosure in document WO2007042885(A2) (67). All 
chemicals necessary for the synthesis were purchased from Sigma-Aldrich.
PD0325901 was dissolved in DMSO at a concentration of 50 mg/ml, then 
resuspended in vehicle (0.5% hydroxypropyl methylcellulose with 0.2% Tween 80)  
at a concentration of 0.5 mg/ml, and injected i.p. (5 mg/kg BW) daily for the 
indicated times. Control mice were injected with vehicle. The same protocol 
was used to inject lactating females for early postnatal treatment.

Quantitative real-time RT-PCR. Total RNA from the LV was prepared using 
the RNeasy minikit (Qiagen). RNA (2 μg) was reverse transcribed using 
SuperScriptIII (Invitrogen). TaqMan probe-based gene expression analy-
ses (Applied Biosystems) for Myh7, Myh6, Nppa, and Nppb (Supplemental 
Table 1) were conducted according to the manufacturer’s instructions. 
Each sample was measured in triplicate, and the relative expression was 
normalized to GAPDH.

Biochemical analysis. Total protein extracts from cells or tissues were pre-
pared by homogenization in RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM  
NaCl, 2 mM EDTA, 1% NP-40, 0.5% Na deoxycholate, and 0.1% SDS) con-
taining a protease and phosphatase inhibitor cocktail (40 μg/ml PMSF, 
20 mM NaF, 1 mM Na3VO4, 10 mM β-glycerophosphate, 10 mM sodium 
pyrophosphate, 2 μg/ml antipain, 2 μg/ml pepstatin A, 20 μg/ml leupeptin, 
and 20 μg/ml aprotinin). Homogenates were centrifuged at 16,100 g for  
15 minutes at 4°C, and the supernatants were collected. Lysates (10–25 μg 
protein) were resolved by SDS-PAGE and analyzed by immunoblotting. 
Antibodies for immunoblots included Raf1 (BD Biosciences); SH-PTP2 
and ERK2 (C-18 and D2, respectively; Santa Cruz Biotechnology Inc.); 
and phospho-MEK1/2, MEK1/2, phospho-p44/42 MAPK, phospho-S6 
(Ser235/236), p38, phospho-p38, phospho-JNK1/2, Akt1, phospho-Akt 
(Ser473), phospho–GSK-3β (Ser9), and phospho-P70S6K (all from Cell 
Signaling Technology). Primary antibody binding was visualized by IRDye 
infrared secondary antibodies using the Odyssey Infrared Imaging System 
(LI-COR Biosciences). Quantification of immunoblots was performed 
using Odyssey version 3.0 software.

Statistics. All data are presented as mean ± SEM. Statistical significance 
was determined using 1- or 2-tailed Student’s t test, 1-way ANOVA, or 2-way  
repeated measure ANOVA, as appropriate. If ANOVA was significant, indi-
vidual differences were evaluated using Bonferroni post-test. Deviation of 
progeny from Mendelian frequency was assessed by χ2 test. Kaplan-Meier 
survival curves were analyzed using the log-rank test. For experiments in 
Figure 10B, significant outliers were identified using Grubbs test. All sta-
tistical analyses were performed with GraphPad Prism 5. For all studies, a 
P value less than 0.05 was considered significant.

Acknowledgments
We thank Angel Sing (Ontario Cancer Institute) for technical 
assistance. This work was supported by NIH grants HL083273 
and R37CA49152 (to B.G. Neel) and Canadian Institutes of 
Health Research grants 153103 (to P.H. Backx) and 106526 (to 
T. Araki). This research also was funded in part by the Ontario 
Ministry of Health and Long Term Care (OMOHLTC). The views 
expressed do not necessarily reflect those of the OMOHLTC. 
P.H. Backx is supported by Career Investigator Awards (I-6891) 
of the Heart and Stroke Foundation of Ontario. X. Wu was sup-
ported by Frederick Banting and Charles Best Canada Gradu-
ate Scholarship. K.-H. Kim was supported in part by graduate 
studentships from the Ontario Graduate Scholarship in Science 
and Technology program.

Received for publication August 29, 2010, and accepted in revised 
form December 15, 2010.

Address correspondence to: Benjamin G. Neel or Toshiyuki Araki, 
Campbell  Family  Cancer  Research  Institute,  Ontario  Cancer 
Institute and Princess Margaret Hospital, University Health Net-
work, MaRS Centre, Toronto Medical Discovery Tower, 8th Floor 
Rm 8-601, 101 College Street, Toronto, Ontario, Canada M5G 
1L7. Phone: 416.581.7726; Fax: 416.581.7698; E-mail: bneel@ 
uhnresearch.ca (B.G. Neel); taraki@uhnres.utoronto.ca (T. Araki).

	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 3      March 2011 

1023

Downloaded on October  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/44929

research article

  1. Dorn GW 2nd, Force T. Protein kinase cascades in 
the regulation of cardiac hypertrophy. J Clin Invest. 
2005;115(3):527–537.

  2. Heineke J, Molkentin JD. Regulation of cardiac 
hypertrophy by intracellular signalling pathways. 
Nat Rev Mol Cell Biol. 2006;7(8):589–600.

  3. Haider  AW,  Larson  MG,  Benjamin  EJ,  Levy  D. 
Increased left ventricular mass and hypertrophy 
are associated with increased risk for sudden death.  
J Am Coll Cardiol. 1998;32(5):1454–1459.

  4. Berenji K, Drazner MH, Rothermel BA, Hill JA. 
Does load-induced ventricular hypertrophy prog-
ress to systolic heart failure? Am J Physiol Heart Circ 
Physiol. 2005;289(1):H8–H16.

  5. Schoenfeld JR, et al. Distinct molecular pheno-
types  in  murine  cardiac  muscle  development, 
growth,  and  hypertrophy.  J  Mol  Cell  Cardiol. 
1998;30(11):2269–2280.

  6. Soor GS, et al. Hypertrophic cardiomyopathy: cur-
rent understanding and treatment objectives. J Clin 
Pathol. 2009;62(3):226–235.

  7. Maron BJ. Hypertrophic cardiomyopathy: a sys-

tematic review. Jama. 2002;287(10):1308–1320.

  8. Anan R, et al. Prognostic implications of novel beta 
cardiac myosin heavy chain gene mutations that 
cause familial hypertrophic cardiomyopathy. J Clin 
Invest. 1994;93(1):280–285.

  9. Marian AJ, Roberts R. Recent advances in the molec-
ular  genetics  of  hypertrophic  cardiomyopathy.  
Circulation. 1995;92(5):1336–1347.

  10. Schwartz K, Carrier L, Guicheney P, Komajda M. 
Molecular  basis  of  familial  cardiomyopathies.  
Circulation. 1995;91(2):532–540.

  11. Niimura H, et al. Mutations in the gene for cardiac 
myosin-binding protein C and late-onset famil-
ial hypertrophic cardiomyopathy. N Engl J Med. 
1998;338(18):1248–1257.

  12. Blair E, et al. Mutations in the gamma(2) subunit 
of AMP-activated protein kinase cause familial 
hypertrophic cardiomyopathy: evidence for the 
central role of energy compromise in disease patho-
genesis. Hum Mol Genet. 2001;10(11):1215–1220.

  13. Oliveira SM, Ehtisham J, Redwood CS, Ostman-
Smith I, Blair EM, Watkins H. Mutation analysis of 
AMP-activated protein kinase subunits in inherited 
cardiomyopathies: implications for kinase func-
tion and disease pathogenesis. J Mol Cell Cardiol. 
2003;35(10):1251–1255.

  14. Murphy  RT,  et  al.  Adenosine  monophosphate-
activated protein kinase disease mimicks hyper-
trophic  cardiomyopathy  and  Wolff-Parkinson-
White syndrome: natural history. J Am Coll Cardiol. 
2005;45(6):922–930.

  15. Rohini A, Agrawal N, Koyani CN, Singh R. Molecu-
lar targets and regulators of cardiac hypertrophy. 
Pharmacol Res. 2010;61(4):269–280.

  16. Malumbres M, Barbacid M. RAS oncogenes: the 

first 30 years. Nat Rev Cancer. 2003;3(6):459–465.

  17. McCubrey JA, et al. Roles of the Raf/MEK/ERK 
pathway in cell growth, malignant transformation 
and drug resistance. Biochim Biophys Acta. 2007; 
1773(8):1263–1284.

  18. Bueno  OF,  Molkentin  JD.  Involvement  of 
extracellular signal-regulated kinases 1/2 in car-
diac hypertrophy and cell death. Circ Res. 2002; 
91(9):776–781.

  19. Lorenz K, Schmitt JP, Vidal M, Lohse MJ. Cardiac 
hypertrophy: targeting Raf/MEK/ERK1/2-signal-
ing. Int J Biochem Cell Biol. 2009;41(12):2351–2355.
  20. Hunter JJ, Tanaka N, Rockman HA, Ross J Jr, Chien 
KR. Ventricular expression of a MLC-2v-ras fusion 
gene induces cardiac hypertrophy and selective dia-
stolic dysfunction in transgenic mice. J Biol Chem. 
1995;270(39):23173–23178.

  21. Zheng M, et al. Sarcoplasmic reticulum calcium 
defect  in  Ras-induced  hypertrophic  cardiomy-
opathy heart. Am J Physiol Heart Circ Physiol. 2004; 
286(1):H424–H433.

  22. Mitchell S, et al. Distinct gene expression profiles in 
adult mouse heart following targeted MAP kinase 
activation. Physiol Genomics. 2006;25(1):50–59.

  23. Glennon PE, Kaddoura S, Sale EM, Sale GJ, Fuller 
SJ, Sugden PH. Depletion of mitogen-activated 
protein kinase using an antisense oligodeoxynu-
cleotide approach downregulates the phenyleph-
rine-induced hypertrophic response in rat cardiac 
myocytes. Circ Res. 1996;78(6):954–961.

  24. Clerk A, Michael A, Sugden PH. Stimulation of the 
p38 mitogen-activated protein kinase pathway in 
neonatal rat ventricular myocytes by the G protein-
coupled receptor agonists, endothelin-1 and phen-
ylephrine: a role in cardiac myocyte hypertrophy?  
J Cell Biol. 1998;142(2):523–535.

  25. Harris IS, Zhang S, Treskov I, Kovacs A, Wein-
heimer  C,  Muslin  AJ.  Raf-1  kinase  is  required 
for cardiac hypertrophy and cardiomyocyte sur-
vival in response to pressure overload. Circulation. 
2004;110(6):718–723.

  26. Bueno OF, et al. The MEK1-ERK1/2 signaling path-
way promotes compensated cardiac hypertrophy in 
transgenic mice. EMBO J. 2000;19(23):6341–6350.
  27. Purcell  NH,  et  al.  Genetic  inhibition  of  cardiac 
ERK1/2  promotes  stress-induced  apoptosis  and 
heart failure but has no effect on hypertrophy in vivo. 
Proc Natl Acad Sci U S A. 2007;104(35):14074–14079.
  28. Tartaglia M, Gelb BD. Noonan syndrome and relat-
ed disorders: genetics and pathogenesis. Annu Rev 
Genomics Hum Genet. 2005;6:45–68.

  29. Bentires-Alj  M,  Kontaridis  MI,  Neel  BG.  Stops 
along the RAS pathway in human genetic disease. 
Nat Med. 2006;12(3):283–285.

  30. Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y. 
The RAS/MAPK syndromes: novel roles of the RAS 
pathway in human genetic disorders. Hum Mutat. 
2008;29(8):992–1006.

  31. Tidyman WE, Rauen KA. The RASopathies: develop-
mental syndromes of Ras/MAPK pathway dysregu-
lation. Curr Opin Genet Dev. 2009;19(3):230–236.

  32. Rauen KA, et al. Proceedings from the 2009 genetic 
syndromes of the Ras/MAPK pathway: From bed-
side to bench and back. Am J Med Genet A. 2010; 
152A(1):4–24.

  33. Chan  G,  Kalaitzidis  D,  Neel  BG.  The  tyrosine 
phosphatase  Shp2  (PTPN11)  in  cancer.  Cancer 
Metastasis Rev. 2008;27(2):179–192.

  34. Tartaglia M, et al. Mutations in PTPN11, encod-
ing the protein tyrosine phosphatase SHP-2, cause 
Noonan syndrome. Nat Genet. 2001;29(4):465–468.
  35. Roberts AE, et al. Germline gain-of-function muta-
tions in SOS1 cause Noonan syndrome. Nat Genet. 
2007;39(1):70–74.

  36. Tartaglia M, et al. Gain-of-function SOS1 muta-
tions cause a distinctive form of Noonan syndrome. 
Nat Genet. 2007;39(1):75–79.

  37. Pandit  B,  et  al.  Gain-of-function  RAF1  muta-
tions cause Noonan and LEOPARD syndromes 
with  hypertrophic  cardiomyopathy.  Nat  Genet. 
2007;39(8):1007–1012.

  38. Razzaque MA, et al. Germline gain-of-function 
mutations in RAF1 cause Noonan syndrome. Nat 
Genet. 2007;39(8):1013–1017.

  39. Schubbert S, et al. Germline KRAS mutations cause 
Noonan syndrome. Nat Genet. 2006;38(3):331–336.
  40. Zenker M, et al. Expansion of the genotypic and 
phenotypic spectrum in patients with KRAS germ-
line mutations. J Med Genet. 2007;44(2):131–135.

  41. Cirstea IC, et al. A restricted spectrum of NRAS 
mutations causes Noonan syndrome. Nat Genet. 
2010;42(1):27–29.

  42. Cordeddu V, et al. Mutation of SHOC2 promotes 
aberrant  protein  N-myristoylation  and  causes 
Noonan-like syndrome with loose anagen hair. Nat 
Genet. 2009;41(9):1022–1026.

  43. Nishikawa T, Ishiyama S, Shimojo T, Takeda K, 
Kasajima T, Momma K. Hypertrophic cardiomy-
opathy  in  Noonan  syndrome.  Acta Paediatr Jpn. 

1996;38(1):91–98.

  44. Sznajer Y, et al. The spectrum of cardiac anomalies 
in Noonan syndrome as a result of mutations in the 
PTPN11 gene. Pediatrics. 2007;119(6):e1325–1331.
  45. Kontaridis MI, Swanson KD, David FS, Barford D, 
Neel BG. PTPN11 (Shp2) mutations in LEOPARD 
syndrome have dominant negative, not activating, 
effects. J Biol Chem. 2006;281(10):6785–6792.

  46. Hanna  N,  et  al.  Reduced  phosphatase  activity 
of SHP-2 in LEOPARD syndrome: consequenc-
es  for  PI3K  binding  on  Gab1.  FEBS  Lett.  2006; 
580(10):2477–2482.

  47. Tartaglia M, et al. Diversity and functional conse-
quences of germline and somatic PTPN11 muta-
tions in human disease. Am J Hum Genet. 2006; 
78(2):279–290.

  48. Porciello R, Divona L, Strano S, Carbone A, Calvieri 
C, Giustini S. Leopard syndrome. Dermatol Online J. 
2008;14(3):7.

  49. Aoki Y, et al. Germline mutations in HRAS proto-
oncogene cause Costello syndrome. Nat Genet. 2005; 
37(10):1038–1040.

  50. Gripp KW, et al. HRAS mutation analysis in Costel-
lo syndrome: genotype and phenotype correlation. 
Am J Med Genet A. 2006;140(1):1–7.

  51. Niihori T, et al. Germline KRAS and BRAF muta-
tions  in  cardio-facio-cutaneous  syndrome.  Nat 
Genet. 2006;38(3):294–296.

  52. Gripp KW, et al. Further delineation of the phe-
notype resulting from BRAF or MEK1 germline 
mutations helps differentiate cardio-facio-cutane-
ous syndrome from Costello syndrome. Am J Med 
Genet A. 2010;143A(13):1472–1480.

  53. Rodriguez-Viciana P, et al. Germline mutations 
in  genes  within  the  MAPK  pathway  cause  car-
dio-facio-cutaneous  syndrome.  Science.  2006; 
311(5765):1287–1290.

  54. Araki T, et al. Mouse model of Noonan syndrome 
reveals cell type- and gene dosage-dependent effects 
of Ptpn11 mutation. Nat Med. 2004;10(8):849–857.
  55. Krenz  M,  Gulick  J,  Osinska  HE,  Colbert  MC, 
Molkentin  JD,  Robbins  J.  Role  of  ERK1/2  sig-
naling  in  congenital  valve  malformations  in 
Noonan syndrome. Proc Natl Acad Sci U S A. 2008; 
105(48):18930–18935.

  56. Nakamura T, et al. Mediating ERK 1/2 signal-
ing rescues congenital heart defects in a mouse 
model of Noonan syndrome. J Clin Invest. 2007; 
117(8):2123–2132.

  57. Nakamura T, Gulick J, Pratt R, Robbins J. Noonan 
syndrome is associated with enhanced pERK activ-
ity, the repression of which can prevent craniofa-
cial malformations. Proc Natl Acad Sci U S A. 2009; 
106(36):15436–15441.

  58. Araki T, Chan G, Newbigging S, Morikawa L, Bron-
son RT, Neel BG. Noonan syndrome cardiac defects 
are caused by PTPN11 acting in endocardium to 
enhance endocardial-mesenchymal transformation. 
Proc Natl Acad Sci U S A. 2009;106(12):4736–4741.

  59. Chen X, et al. Endogenous expression of Hras(G12V) 
induces developmental defects and neoplasms with 
copy number imbalances of the oncogene. Proc Natl 
Acad Sci U S A. 2009;106(19):7979–7984.

  60. Marin TM, et al. Rapamycin reverses hypertrophic 
cardiomyopathy in a mouse model of LEOPARD 
syndrome–associated  PTPN11  mutation.  J  Clin 
Invest. 2011;121(3):1026–1043.

  61. Allanson JE, et al. The face of Noonan syndrome: 
Does phenotype predict genotype. Am J Med Genet A.  
2010;152A(8):1960–1966.

 62. Hasle  H.  Malignant  diseases  in  Noonan  syn-
drome and related disorders. Horm Res. 2009;72 
suppl 2:8–14.

  63. Ross J Jr, Sobel BE. Regulation of cardiac contrac-

tion. Annu Rev Physiol. 1972;34:47–90.

  64. Nakagawa O, et al. Rapid transcriptional activa-
tion and early mRNA turnover of brain natriuretic 
peptide in cardiocyte hypertrophy. Evidence for 

1024	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 3      March 2011

Downloaded on October  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/44929

research article

brain natriuretic peptide as an “emergency” cardiac 
hormone against ventricular overload. J Clin Invest. 
1995;96(3):1280–1287.

  65. Takeda N, et al. Cardiac fibroblasts are essential for 
the adaptive response of the murine heart to pres-
sure overload. J Clin Invest. 2010;120(1):254–265.

  66. Thum T, et al. MicroRNA-21 contributes to myocar-
dial disease by stimulating MAP kinase signalling in 
fibroblasts. Nature. 2008;456(7224):980–984.

  67. Barrett SD, et al. The discovery of the benzhydrox-
amate MEK inhibitors CI-1040 and PD 0325901. 
Bioorg Med Chem Lett. 2008;18(24):6501–6504.

  68. Chen PC, et al. Activation of multiple signaling 
pathways causes developmental defects in mice with 
a Noonan syndrome–associated Sos1 mutation.  
J Clin Invest. 2010;120(12):4353–4365.

  69. Bertola DR, Pereira AC, de Oliveira PS, Kim CA, 
Krieger JE. Clinical variability in a Noonan syn-
drome family with a new PTPN11 gene mutation. 

Am J Med Genet A. 2004;130A(4):378–383.

  70. Bueno OF, et al. The dual-specificity phosphatase 
MKP-1 limits the cardiac hypertrophic response in 
vitro and in vivo. Circ Res. 2001;88(1):88–96.

  71. Xu J, Ismat FA, Wang T, Lu MM, Antonucci N, 
Epstein JA. Cardiomyocyte-specific loss of neuro-
fibromin promotes cardiac hypertrophy and dys-
function. Circ Res. 2009;105(3):304–311.

  72. Ieda M, et al. Cardiac fibroblasts regulate myocar-
dial proliferation through beta1 integrin signaling. 
Dev Cell. 2009;16(2):233–244.

  73. Miragoli M, Gaudesius G, Rohr S. Electrotonic 
modulation  of  cardiac  impulse  conduction  by 
myofibroblasts. Circ Res. 2006;98(6):801–810.

  74. Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a 
review of its peripheral actions and interactions. Int 
J Obes Relat Metab Disord. 2002;26(11):1407–1433.

  75. Bjorbaek  C,  et  al.  Divergent  roles  of  SHP-2  in 
ERK activation by leptin receptors. J Biol Chem. 

2001;276(7):4747–4755.

  76. Zhang  EE,  Chapeau  E,  Hagihara  K,  Feng  GS. 
Neuronal  Shp2  tyrosine  phosphatase  controls 
energy balance and metabolism. Proc Natl Acad Sci 
U S A. 2004;101(45):16064–16069.

  77. Su  IH,  et  al.  Ezh2  controls  B  cell  development 
through  histone  H3  methylation  and  Igh  rear-
rangement. Nat Immunol. 2003;4(2):124–131.

  78. Zhang SQ, et al. Shp2 regulates SRC family kinase 
activity and Ras/Erk activation by controlling Csk 
recruitment. Mol Cell. 2004;13(3):341–355.

  79. Zobel C, Kassiri Z, Nguyen TT, Meng Y, Backx PH. 
Prevention of hypertrophy by overexpression of 
Kv4.2 in cultured neonatal cardiomyocytes. Circu-
lation. 2002;106(18):2385–2391.

  80. Chan G, et al. Leukemogenic Ptpn11 causes fatal 
myeloproliferative disorder via cell-autonomous 
effects on multiple stages of hematopoiesis. Blood. 
2009;113(18):4414–4424.

	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 3      March 2011 

1025

